Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
As a seasoned venture capitalist, if I can give you one piece of advice, it’s this:
Do not invest on IPO Day.
I don’t care how big the IPO is.
Elon Musk is set to take Starlink public this year in what will be the biggest IPO in history.
But instead of buying Starlink, you should look into this $30 stock - and you should do it right now, before the potential IPO today.
This company - whose name and ticker is revealed for FREE in this short video - is poised to rocket 100% or more in the next year off the back of the coming SpaceX IPO.
And you can get shares today.
Sincerely,
James Altucher
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
Written by Jeffrey Neal Johnson. Publication Date: 2/24/2026.
Key Points
- Johnson & Johnson has maintained an impressive streak of increasing its dividend payouts for generations, rewarding long-term shareholders with reliable income.
- Management is driving future expansion by focusing on high-growth pharmaceutical assets and cutting-edge medical technologies, such as robotics.
- Investors looking for shelter from market volatility benefit from a stock that historically moves much less than the broader market indices.
- Special Report: [Sponsorship-Ad-6-Format3]
While the technology sector faces renewed volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming. Johnson & Johnson (NYSE: JNJ) is trading near all-time highs of roughly $245 per share, creating a divergence that has attracted Wall Street's attention.
This rally runs counter to the common perception of the healthcare giant as a slow-moving, boring stock. Over the past 30 days, shares have climbed about 14%, significantly outperforming the broader market during a period of uncertainty. The price action suggests institutional money is rotating out of riskier assets and placing a premium on stability, reliable cash flow, and execution.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
For investors watching the ticker today, Feb. 24, 2026, note a specific calendar event: it is the ex-dividend date for Johnson & Johnson. That means the stock price will likely adjust downward by the upcoming quarterly dividend amount of $1.30 per share — a mechanical market move rather than a reflection of business performance. For income-focused investors, this technical dip can represent an attractive entry point rather than a reason to sell.
64 Years of Unbroken Growth
The primary case for holding Johnson & Johnson during turbulent markets is its financial stability and role as a portfolio stabilizer. The company is a member of the elite group of Dividend Kings — firms that have raised their dividend for at least 50 consecutive years.
Johnson & Johnson has now increased its dividend for 64 consecutive years, a track record that spans recessions, market crashes, and geopolitical conflicts. That consistency is a rare commodity in a market that often prizes speculative growth.
The stock yields roughly 2.12% based on an annual payout of $5.20 per share. While higher yields exist in bonds or riskier sectors, J&J combines yield with growth and safety. Management projects free cash flow of about $21 billion in 2026, a level of cash generation that helps secure the dividend, fund R&D, and cover legal expenses without heavy borrowing.
For risk-averse investors, one compelling metric is the stock's Beta — a measure of how much a stock moves relative to the overall market (S&P 500). A Beta of 1.0 moves in lockstep with the market; Johnson & Johnson's Beta is approximately 0.35, meaning it's historically about 65% less volatile than the broader market. When tech stocks swing, J&J tends to hold its ground. Adding JNJ to a tech-heavy portfolio can act as a mathematical shock absorber, dampening overall volatility while maintaining equity exposure.
Beyond the Patent Cliff: The Road to $100 Billion
A common misconception about "safe" stocks is that they can't grow. Johnson & Johnson is disproving that with a strategic pivot that appears to be paying off. Management projects 2026 full-year revenue to surpass the $100 billion mark for the first time in company history, with adjusted earnings per share around $11.53.
This growth stems from a reinvigorated pharmaceutical division, now branded as Innovative Medicine. Investors once worried about a patent cliff after Stelara lost exclusivity in 2025, but J&J has offset that decline with the rise of new blockbusters.
Two key assets are driving this resilience:
- Darzalex: This oncology drug is generating roughly $14 billion in annual sales and has helped cement J&J's leadership in multiple myeloma therapy worldwide.
- Tremfya: Positioned as a successor to Stelara, Tremfya posted strong three-year remission data for ulcerative colitis, demonstrating the company's ability to retain share in a competitive immunology market.
The Tech in MedTech: High-Margin Technologies
Growth extends beyond pharmaceuticals into the MedTech division, which has shifted toward higher-growth, higher-margin technologies. A notable addition is Shockwave Medical, whose intravascular lithotripsy (IVL) technology uses sonic pressure waves to break up calcified plaque in arteries — an upgrade over traditional angioplasty balloons. Owning this technology strengthens J&J's cardiovascular portfolio and complements its heart pump technologies and surgical businesses.
The company is also advancing in robotics. The submission of its Ottava robotic surgical system for FDA approval signals its intent to compete in the expanding soft-tissue robotics market. These high-tech devices typically carry higher profit margins and foster durable relationships with hospital systems, creating a long-term earnings tailwind beyond basic surgical supplies.
Addition by Subtraction: The Orthopedics Strategy
To sustain growth and improve margins, management is reshaping the corporate structure. A major development is the potential separation of the DePuy Synthes orthopedics business. While originally planned as a spin-off, reports now suggest the company is exploring a large sale of the unit.
Divesting the orthopedics business would be a classic addition-by-subtraction move. Orthopedics is a mature, lower-growth segment compared with booming fields like oncology and advanced cardiovascular devices. Shedding this slower unit could boost overall revenue growth and profit margins. A sale would also provide a substantial cash infusion — potentially billions — that could be deployed for acquisitions, debt reduction, or share buybacks.
Legal risks remain an important consideration. Johnson & Johnson continues to face litigation over talc products, including a recent $1.5 billion verdict that keeps the issue in the headlines. A new commercial lawsuit from Bayer over prostate cancer drug marketing has added further noise.
Nevertheless, the market's recent rally suggests investors are focusing on fundamentals. Bulls argue J&J has the financial depth to manage these liabilities without disrupting operations. With more than $20 billion in cash and marketable securities, potential proceeds from an orthopedics sale, and roughly $21 billion in annual free cash flow, the company has a financial fortress capable of absorbing settlements. For now, legal matters appear likely to remain balance-sheet items rather than existential threats to the dividend or business.
Capital Preservation With Upside
Johnson & Johnson has evolved from a slow-moving conglomerate into a more focused, high-tech healthcare company. After spinning off its consumer health division (Kenvue (NYSE: KVUE)) and potentially divesting orthopedics, management is concentrating on higher-growth opportunities in pharmaceuticals and medical technology.
Though the stock is no longer a deep-value bargain and trades near all-time highs, it offers a blend of capital preservation and growth that is increasingly rare. The combination of a 64-year dividend growth streak, a low volatility profile, and a clear path to $100 billion in revenue makes J&J a compelling option for 2026. For investors weary of the technology sector's unpredictability, Johnson & Johnson demonstrates that, in the current environment, boring can be both beautiful and profitable.
America's Most Envied Shopping Districts in 2026
Written by MarketBeat Staff. Publication Date: 3/3/2026.
We surveyed more than 3,000 people about the most envied shopping districts in the country. The results reveal what people value.
Some cities win hearts with luxury storefronts, others with independent makers, and surprisingly often, with a really good bookstore.
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
This isn't just a list of where people like to shop; it's a map of what Americans miss, envy, and quietly wish they had closer to home.
Key Findings
California is the most envied retail state in the country.
Four California districts land in the top 10 (Carmel-by-the-Sea, Abbot Kinney, Rodeo Drive, State Street). The appeal ranges from luxury (Beverly Hills) to quirky maker culture (Venice) to art-forward enclaves (Carmel Arts & Design, Hayes Valley). Respondents said California's brand of walkable, creative, slightly dreamy retail clearly travels well nationwide.
New York has two personalities — and America envies both.
New York shows up in two distinct forms:
- The global icons: SoHo and Fifth Avenue (both top five).
- The neighborhood darlings: Williamsburg's Bedford Ave and other smaller-scale favorites.
The split suggests Americans admire New York's big, glamorous shopping temples but also crave the smaller, more "livable" neighborhoods locals brag about. Comparable neighborhood favorites around the country include Saratoga Springs, Syracuse's Armory Square, and Chapel Hill's college-town charm.
The South's strongest entries lean heavily on charm, not luxury.
Tennessee alone places three districts in the top third (12 South, Germantown, Downtown Franklin), all featuring indie boutiques and hyper-local retailers.
The Carolinas follow the same pattern: Greenville, Charleston, Beaufort, Wilmington, and Chapel Hill all rank highly, known for small bookstores and long-running local shops.
The South's retail envy is less about big brands and more about community-first shopping streets with personality.
College towns feature prominently.
Ann Arbor, Chapel Hill, Burlington, Hanover, Princeton, and Providence all appear, often anchored by beloved indie bookstores or niche makers.
These aren't big cities, but their districts rank alongside major metros, suggesting walkability + culture + bookstores is a stronger draw than sheer size or spending power.
Hawaii's shopping districts feature unusually high appeal — and not just because of tourists.
Two Hawaiian districts make the upper tier (Kalākaua Avenue and Haleiwa Town), both blending retail with cultural performance, surf culture, and local makers.
People envy shopping experiences that feel like a cultural moment, not just a place to buy gifts.
Texas shows a very specific identity: maker-forward, not mall-forward.
The Pearl District in San Antonio, South Congress in Austin, Bishop Arts in Dallas, and The Woodlands all appear, but none are traditional mall corridors.
Instead, the appeal is creativity, reuse, and street-level discovery. Texas districts rank well when they feel handcrafted, not corporate.
Colorado and Oregon form an "outdoor retail" corridor.
Pearl Street Mall (Boulder), Larimer Square and Cherry Creek (Denver), Powell's and the Hawthorne District (Portland), and towns like Whitefish and Bozeman further north share a pattern:
- Independent outdoor gear
- Artisans
- Strong coffee culture
- Bookstores
Western mountain towns have the strongest "character-per-capita."
Jackson, Stowe, Whitefish, Bozeman, Ketchum, Moab — all small but memorable. Their appeal combines tourism, artisan shops, and dramatic scenery, which makes even a tiny main street feel like an event.
Final Thoughts
When we analyzed all 194 envied districts, a clear pattern emerged: Americans don't envy the biggest or the most expensive places — they envy the most distinctive ones.
They want places with a sense of story: where you wander, not just buy. Places with a great bookstore, a beloved coffee shop, a maker's market, or a street that feels like nowhere else. Luxury still has its place, but identity wins.
This email content is a paid sponsorship sent on behalf of Paradigm Press, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you have questions or concerns about your subscription, don't hesitate to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 North Reid Place #620, Sioux Falls, S.D. 57103. United States of America..